Fort Towson

Almoxatone (MD-780,236) is a selective and reversible inhibitor of MAO-B.[1][2] It was patented as an antidepressant and antiparkinsonian agent but was never marketed.[3]

See also

References

  1. ^ Tipton KF, Fowler CJ, McCrodden JM, Strolin Benedetti M (January 1983). "The enzyme-activated irreversible inhibition of type-B monoamine oxidase by 3-(4-[(3-chlorophenyl)methoxy]phenyl)-5-[(methylamino) methyl]-2-oxazolidinone methanesulphonate (compound MD 780236) and the enzyme-catalysed oxidation of this compound as competing reactions". The Biochemical Journal. 209 (1): 235–42. doi:10.1042/bj2090235. PMC 1154077. PMID 6847610.
  2. ^ Dostert P, Strolin Benedetti M, Guffroy C (March 1983). "Different stereoselective inhibition of monoamine oxidase-B by the R- and S-enantiomers of MD 780236". The Journal of Pharmacy and Pharmacology. 35 (3): 161–5. doi:10.1111/j.2042-7158.1983.tb04297.x. PMID 6132973. S2CID 10074323.
  3. ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.


source: https://en.wikipedia.org/wiki/Almoxatone